Research and Development Expense of Maze Therapeutics, Inc. from 31 Mar 2024 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
- Summary
-
Maze Therapeutics, Inc. quarterly and annual Research and Development Expense in USD history and change rate from 31 Mar 2024 to 31 Dec 2025.
- Maze Therapeutics, Inc. Research and Development Expense for the quarter ending 31 Dec 2025 was $27,570,000, a 24% increase year-over-year.
- Maze Therapeutics, Inc. Research and Development Expense for the twelve months ending 31 Dec 2025 was $108,448,000, a 30% increase year-over-year.
- Maze Therapeutics, Inc. annual Research and Development Expense for 2025 was $108,448,000, a 30% increase from 2024.
- Source SEC data
- View on sec.gov
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)
Maze Therapeutics, Inc. Quarterly Research and Development Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $108,448,000 | $27,570,000 | +$5,354,000 | +24% | 01 Oct 2025 | 31 Dec 2025 | 10-K | 25 Mar 2026 | 2025 | FY |
| Q3 2025 | $103,094,000 | $25,190,000 | +$5,333,000 | +27% | 01 Jul 2025 | 30 Sep 2025 | 10-Q | 06 Nov 2025 | 2025 | Q3 |
| Q2 2025 | $97,761,000 | $28,108,000 | +$8,562,000 | +44% | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q2 |
| Q1 2025 | $89,199,000 | $27,580,000 | +$5,703,000 | +26% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q1 |
| Q4 2024 | $83,496,000 | $22,216,000 | 01 Oct 2024 | 31 Dec 2024 | 10-K | 25 Mar 2026 | 2025 | FY | ||
| Q3 2024 | $19,857,000 | 01 Jul 2024 | 30 Sep 2024 | 10-Q | 06 Nov 2025 | 2025 | Q3 | |||
| Q2 2024 | $19,546,000 | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 12 Aug 2025 | 2025 | Q2 | |||
| Q1 2024 | $21,877,000 | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 14 May 2025 | 2025 | Q1 |
Maze Therapeutics, Inc. Annual Research and Development Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $108,448,000 | +$24,952,000 | +30% | 01 Jan 2025 | 31 Dec 2025 | 10-K | 25 Mar 2026 | 2025 | FY |
| 2024 | $83,496,000 | 01 Jan 2024 | 31 Dec 2024 | 10-K | 25 Mar 2026 | 2025 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.